Saturday 17 October 2026
Export CYTOF’s income statement to Excel — free account
Altamira Therapeutics Ltd.
CYTOF Healthcare Biotechnology
Altamira Therapeutics Ltd.’s revenue for fiscal 2022 (year ended December 2022) was $320,300.00.
0.09
0.00
0.00%
Follow CYTOF
| Jun '25 | Jun '24 | Jun '23 | Jun '22 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | (385.74%) | (514.91%) |
+8 more TTM periods Free account |
|
| 0.00% | 0.00% | (214.75%) | (236.82%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 807.49% | 426.90% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(10.72) | (11.48) | (29.37) | (30.09) | |
Capital Expenditures |
— | — | — | (5.68) | |
| Other line items | |||||
Cash ROIC |
(237.82%) | (172.69%) | (4,381.98%) | (223.93%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 2.37 | 1.86 | |
Inventory Turnover |
— | — | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 192.55 | 313.21 | |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | |
Tax Rate |
— | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | — | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.90 | 0.74 | |
Depreciation/Fixed assets |
1.61 | 0.00 | 0.00 | 0.29 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (36.63) | |
Revenue per Share |
— | — | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
— | — | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates · fundamentals updated 14 Oct 2026